Logo image
Postural control in lowlanders with COPD travelling to 3100 m; data from a randomized trial evaluating the effect of preventive dexamethasone treatment
Journal article   Open access   Peer reviewed

Postural control in lowlanders with COPD travelling to 3100 m; data from a randomized trial evaluating the effect of preventive dexamethasone treatment

Lara Muralt, Michael Furian, Mona Lichtblau, Sayaka S Aeschbacher, Ross Clark, Bermet Estebesova, Ulan Sheraliev, Niriddin Marazhapov, Batyr Osmonov, Maya Bisang, …
Frontiers in Physiology, Vol.9, 752
2018
pdf
PDF - Published Version (Open Access)1.77 MBDownloadView
Published VersionPDF - Published Version (Open Access)CC BY V4.0 Open Access
url
https://doi.org/10.3389/fphys.2018.00752View
Published Version

Abstract

chronic obstructive pulmonary disease altitude hypoxia postural control Dexamethasone acute mountain sickness
Objective: To evaluate the effects of acute exposure to high altitude and preventive dexamethasone treatment on postural control in patients with chronic obstructive pulmonary disease (COPD). Methods: In this randomized, double-blind parallel-group trial, 104 lowlanders with COPD GOLD 1-2 age 20-75 y, living near Bishkek (760 m), were randomized to receive either dexamethasone (2x4 mg/d p.o.) or placebo on the day before ascent and during a 2-day sojourn at Tuja-Ashu high altitude clinic (3100 m), Kyrgyzstan. Postural control was assessed with a Wii Balance BoardTM at 760 m and one day after arrival at 3100 m. Patients were instructed to stand immobile on both legs with eyes open during five tests of 30 s each, while the center of pressure path length (PL) was measured. Results: With ascent from 760 to 3100 m the PL increased in the placebo group from median (quartiles) 29.2 (25.8 ; 38.2) to 31.5 (27.3 ; 39.3) cm (P< 0.05); in the dexamethasone group the corresponding increase from 28.8 (22.8 ; 34.5) to 29.9 (25.2 ; 37.0) cm was not significant (P=0.10). The mean difference (95% CI) between dexamethasone and placebo groups in altitude-induced changes (treatment effect) was -0.3 (-3.2 to 2.5) cm, (P=0.41). Multivariable regression analysis confirmed a significant increase in PL with higher altitude (coefficient 1.6, 95% CI 0.2 to 3.1, P=0.031) but no effect of dexamethasone was shown (coefficient -0.2, 95% CI -4.0 to 3.6, P=0.925), even when controlled for several potential confounders. PL changes were related more to antero-posterior than lateral sway. 22 of 104 patients had an altitude-related increase in the antero-posterior sway velocity of >25%, what has been associated with an increased risk of falls in previous studies. Conclusions: Lowlanders with COPD travelling from 760 to 3100 m revealed postural instability 24 h after arriving at high altitude, and this was not prevented by dexamethasone.

Details

Metrics

29 File views/ downloads
350 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Web Of Science research areas
Physiology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image